BGMS
Bio Green Med Solution, Inc.·Healthcare
1.01
0.129%(−0.00)
Market ClosedLast Updated: — ET
52W L: $0.7352W H: $100.80
BGMS NEWS
globenewswire.com
Mar 30
BIO GREEN MED SOLUTION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
KUALA LUMPUR, MALAYSIA, March 30, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. ("BGMS," the "Company" or “we,” formerly Cyclacel Pharmaceuticals, Inc.) (NASDAQ: BGMS), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced fourth quarter and full year 2025 financial results and provided a business update.
defenseworld.net
Mar 11
Cyclacel Pharmaceuticals (NASDAQ:BGMS) vs. Syros Pharmaceuticals (NASDAQ:SYRS) Head to Head Analysis
Syros Pharmaceuticals (NASDAQ: SYRS - Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership. Analyst Ratings This is a breakdown of
defenseworld.net
Feb 7
Analyzing Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)
Calliditas Therapeutics AB (publ) (NASDAQ: CALT - Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation. Insider and Institutional Ownership 2.8%
defenseworld.net
Feb 7
Comparing Achaogen (OTCMKTS:AKAOQ) and Cyclacel Pharmaceuticals (NASDAQ:BGMS)
Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) and Achaogen (OTCMKTS:AKAOQ - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership. Institutional and Insider Ownership 23.6% of Cyclacel Pharmaceuticals
